Hsbc Holdings PLC Sells 30,440 Shares of Theravance Biopharma, Inc. $TBPH

Hsbc Holdings PLC cut its holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) by 62.2% in the fourth quarter, Holdings Channel.com reports. The fund owned 18,477 shares of the biopharmaceutical company’s stock after selling 30,440 shares during the quarter. Hsbc Holdings PLC’s holdings in Theravance Biopharma were worth $354,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. JPMorgan Chase & Co. lifted its stake in shares of Theravance Biopharma by 78.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 213,104 shares of the biopharmaceutical company’s stock valued at $3,111,000 after purchasing an additional 93,591 shares during the last quarter. UBS Group AG boosted its holdings in Theravance Biopharma by 10.9% in the fourth quarter. UBS Group AG now owns 570,425 shares of the biopharmaceutical company’s stock worth $10,673,000 after purchasing an additional 56,255 shares in the last quarter. Ellsworth Advisors LLC acquired a new position in Theravance Biopharma during the fourth quarter worth $670,000. Pacer Advisors Inc. acquired a new position in Theravance Biopharma during the fourth quarter worth $6,342,000. Finally, Sierra Summit Advisors LLC bought a new position in Theravance Biopharma during the fourth quarter valued at about $1,111,000. Institutional investors and hedge funds own 99.10% of the company’s stock.

Theravance Biopharma Price Performance

Shares of Theravance Biopharma stock opened at $16.93 on Friday. The company has a market cap of $872.79 million, a PE ratio of 7.70 and a beta of 0.17. The firm has a fifty day moving average price of $16.62 and a two-hundred day moving average price of $17.17. Theravance Biopharma, Inc. has a fifty-two week low of $10.82 and a fifty-two week high of $21.03.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings data on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter. The company had revenue of $17.70 million for the quarter. Theravance Biopharma had a return on equity of 18.84% and a net margin of 104.34%. Analysts expect that Theravance Biopharma, Inc. will post 1.54 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have weighed in on the company. JonesTrading cut Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Monday, June 29th. Zacks Research lowered Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Monday, June 8th. TD Cowen raised their price objective on Theravance Biopharma from $13.00 to $15.00 and gave the company a “hold” rating in a research note on Monday, March 23rd. BTIG Research lowered Theravance Biopharma from a “buy” rating to a “neutral” rating in a report on Monday, June 29th. Finally, B. Riley Financial upped their target price on Theravance Biopharma from $14.00 to $17.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 7th. Eight investment analysts have rated the stock with a Hold rating, According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $19.40.

Insider Transactions at Theravance Biopharma

In related news, major shareholder Eli Samaha sold 37,799 shares of Theravance Biopharma stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $17.00, for a total transaction of $642,583.00. Following the sale, the insider directly owned 9,174,453 shares of the company’s stock, valued at $155,965,701. This trade represents a 0.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Rhonda Farnum sold 13,314 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $16.39, for a total value of $218,216.46. Following the transaction, the senior vice president owned 232,457 shares in the company, valued at $3,809,970.23. This represents a 5.42% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 350,011 shares of company stock worth $6,008,309. 7.65% of the stock is owned by company insiders.

Theravance Biopharma Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.